Structural, functional & molecular neuroimaging biomarkers for AD

November 18, 2023
< 1 mins

Category: Published research

Neuroimaging biomarkers are now routinely incorporated into AD clinical trials and are increasingly used in clinical practice. This paper broadly describes the development and use of these biomarkers as they relate to AD.

[button]Download[/button]

Topic: Published research

More Resources

02/20/2026

NeuroQuant® PET: FDA 510(k)-Pending Advancement in Molecular Dementia Imaging

FDA 510(k)-Pending NeuroQuant® PET delivers automated, standardized quantification for amyloid, tau, and FDG imaging in dementia care.

Blogs, Product updates

02/19/2026

How Cortechs.ai Protects ePHI: HIPAA‑Aligned Controls—and Beyond

Cortechs.ai’s HIPAA-aligned, defense-in-depth security safeguards ePHI across AI workflows—exceeding baseline compliance standards.

Blogs

02/11/2026

NeuroQuant Normative Database: Advancing Age‑ and Sex‑Specific Brain Volumetry

Learn how the latest updates to the NeuroQuant normative database white paper strengthen age- and sex-specific brain volumetry and enhance clinical confidence.

Blogs

02/06/2026

NeuroQuant Normative Database: A Standard for Age- and Sex-Specific Brain Volumetry

Whitepaper: How Cortechs.ai’s normative database was created to accurately compare an individual’s brain structure volume to a healthy population.

Whitepapers

01/22/2026

Reflecting on a Transformative Year at Cortechs.ai

As we enter 2026, we want to take a moment to reflect on what has been a truly impactful year at Cortechs.ai.

Blogs

12/18/2025

Reimbursement Essentials for Quantitative Imaging: Key Takeaways From Our Expert Webinar

Our reimbursement webinar walked through best practices for billing, coding, and securing payment for NeuroQuant and OnQ Prostate, helping inform providers.

Our solutions

Our solutions

About

Support

Resources